Minister for Innovation: Mirada UK leader in AI-powered medical technology
Mirada Medical recognised by Lord Bethell for enhancing cancer care with innovative Artificial Intelligence (AI) technology
Oxford, 17 March 2021: Mirada Medical was been recognised by Lord Bethell, Minister for Innovation, for delivering pioneering AI technology to the front line of cancer care. The Minister specifically called out Mirada’s AI-powered, DLCExpert technology. In a series of Tweets about the NHS AI in Health and Care Awards, he also highlighted Mirada’s work in evidencing how AI reduces time to treatment for cancer patients, as well as ensuring a consistent standard of care.
The UK is leading the way in AI for cancer care
AI is a powerful tool for making cancer radiotherapy treatment faster and more precise. As much of this innovation is being driven out of the UK, the NHS should be first in line to benefit from these new technologies.
Mirada Medical was the first company globally to deliver FDA cleared and clinically approved AI technology that automates the process of outlining organs being scanned for radiation treatment planning. This is typically a complex and time-consuming manual task carried out by clinicians. Transitioning to an automated approach frees up cancer care teams to see more patients and delivers better treatment outcomes.
The NHS has recognized the potential of this AI technology and recently awarded Mirada Medical two grants under the NHS AI in Health and Care Awards to support further development of its solutions. Lord Bethell today also recognized Mirada Medical as a leader in AI innovation and an NHS partner of choice.
Fast-tracking AI technology to the front line
Part of Mirada’s NHS AI in Health and Care Award funding is being used to help more hospitals access AI technology at this critical time. Mirada’s NHS Zero Touch Accelerator program is designed to significantly reduce the timescale for AI automation technology to be live in cancer clinics, helping them to maintain cancer care during the pandemic and support more patients impacted by the backlog. Mirada technology is available free of charge for three months and the implementation process has been reduced to one week, with minimal need to divert staff from their day jobs. Once installed, Mirada’s world-class experts will work remotely with healthcare teams to optimize the technology for their specific needs and requirements.
“The UK is a global leader when it comes to driving innovation in AI-based medical technology. However, during this current crisis, being a world leader means nothing if we cannot get technology into the hands of cancer care teams. That is why Mirada is delighted to announce the launch of its NHS Zero Touch Accelerator program to support cancer clinicians and patients at this critical time,” said Sarah Bond, Chief Product Officer, Mirada Medical. “As a key NHS partner, Mirada is providing a fast and cost-effective way for hospitals to access our technology to tackle the cancer care backlog. However, by embedding AI into radiation treatment workflows now, we can also help the NHS prepare for the anticipated future growth in demand for cancer treatment.”
Mirada Medical is a leading international brand in medical imaging. The company develops advanced technology AI-based applications that help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.
The company specializes in simplifying technically complex image processing tasks, allowing clinicians to diagnose disease, assess response to treatment, and plan radiation therapy or surgical intervention more confidently. Mirada’s advanced technology products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.
020 3997 1087